HAIC联合仑伐替尼和PD-1抗体对比HAIC联合仑伐替尼转化治疗肝细胞癌的回顾性研究

doi:10.3969/j.issn.1009-976X.2024.05.003

摘要/Abstract

摘要： 目的回顾性分析65例中晚期肝细胞癌患者分别使用HAIC联合仑伐替尼和PD-1抗体与HAIC联合仑伐替尼转化切除的疗效及预后。方法回顾性收集中山市人民医院自2020年3月至2023年3月期间获得成功转化切除的65例肝细胞癌患者,根据治疗方案不同分为联合组（HAIC联合仑伐替尼和PD-1抗体）和对照组（HAIC联合仑伐替尼）,对两组患者的总生存期（OS）、无疾病进展生存期（PFS）、治疗相关的不良反应进行统计分析。结果 65例肝细胞癌患者根据 RECIST 1.1和mRECIST标准分别评估治疗,mRECIST标准,联合组PR 29例（74.4%）,ORR 35例（89.7%）,DCR 37例（94.9%）;对照组,PR 9例（74.4%）,ORR 17例（65.4%）,DCR 24例（92.3%）;总体中位生存时间约36个月,总体中位无复发生存期约28个月。其中联合组患者的中位生存时间为40个月,中位无复发生存期为32个月。对照组患者的中位生存时间为29个月、中位无复发生存期为25个月。联合组的PR、ORR、PR、OS、RFS均明显高于对照组（P<0.005）。结论 HAIC联合仑伐替尼和PD-1抗体可为中晚期HCC患者带来更显著的生存优势,有效延长其生存期,改善其生存质量。

关键词: 肝细胞癌, 肝动脉灌注化疗, FOLFOX方案, 联合治疗

Abstract: Objective To retrospectively analyze the efficacy and prognosis of HAIC combined with lenvatinib and PD-1 antibody in the treatment of hepatocellular carcinoma in patients with intermediate and advanced hepatocellular carcinoma in our center. Methods Sixty-five patients admitted to Zhongshan People′s Hospital from March 2020 to March 2023 were retrospectively collected and divided into a combination group （HAIC combined with lenvatinib and PD-1 antibody） and a control group （HAIC combined with lenvatinib） according to the different treatment regimens, and the overall survival （OS）, disease progression-free survival （PFS）, and treatment-related adverse effects of the patients in the two groups were statistically analyzed. Results Sixty-five patients with hepatocellular carcinoma were evaluated for treatment according to RECIST 1.1 and mRECIST criteria, respectively, According to the mRECIST criteria, there were 29 cases （74.4%） of PR, 35 cases （89.7%） of ORR, and 37 cases （94.9%） of DCR in the combined group; In the control group, there were 9 cases of PR （74.4%）, 17 cases of ORR （65.4%）, and 24 cases of DCR （92.3%）; the overall median survival time was about 36 months, and the overall median relapse-free survival was about 28 months. The median survival time for patients in the combination group was 40 months, and the median relapse-free survival was 32 months. Patients in the control group had a median survival time of 29 months and a median relapse-free survival of 25 months. The PR, ORR, OS and RFS of the combination group were significantly higher than those of the control group, which were statistically different. Conclusion HAIC combined with lenvatinib and PD-1 antibody can bring more significant survival advantages for patients with intermediate and advanced HCC, effectively prolonging the survival of intermediate and advanced patients and improving the quality of patients′ survival.

Key words: hepatocellular carcinoma, hepatic artery perfusion chemotherapy, FOLFOX regimen, combination therapy

中图分类号:

R735.7

黄东东, 田丰, 方郁晖, 邱益霖, 何坤. HAIC联合仑伐替尼和PD-1抗体对比HAIC联合仑伐替尼转化治疗肝细胞癌的回顾性研究[J]. 岭南现代临床外科, 2024, 24(05): 284-290.

HUANG Dong-dong, TIAN Feng, FANG Yu-hui, QIU Yi-lin, HE Kun. A retrospective study of HAIC in combination with lenvatinib and PD-1 antibody versus HAIC in combination with lenvatinib for the translational treatment of hepatocellular carcinoma[J]. Lingnan Modern Clinics In Surgery, 2024, 24(05): 284-290.

参考文献

[1] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(2): 143-168.
[2] 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(06): 600-616.
[3] Lyu N, LinY, Kong Y, et al. FOXAI: a phase Ⅱ trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut, 2018, 67(2): 395-396.
[4] He MK, Le Y, Li QJ, et al.Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1): 83.
[5] He M, Li Q, Zou R, et al.Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960.
[6] Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation[J]. J Clin Invest, 2015, 125(1): 25-32.
[7] Deng Y, Chen QS, Huang WF, et al.XPA serves as an autophagy and apoptosis inducer by suppressing hepatocellular carcinoma in a PI3K/Akt/mTOR dependent manner[J]. J Gastrointest Oncol, 2021, 12(4): 1797-810.
[8] Huang A, Yang XR, Chung WY, et al.Targeted therapy for hepatocellular carcinoma[J]. Signal Transduct Target Ther, 2020, 5(1): 146.
[9] Luo X, He X, Zhang X, et al.Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy[J]. MedComm, 2024, 5(2): e474.
[10] Zhang W, Tong S, Hu B, et al.Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase Ⅱ trial[J]. J Immunother Cancer, 2023, 11(9): e007366.
[11] Peng Z, Fan W, Zhu B, et al.Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase Ⅲ, Randomized Clinical Trial (LAUNCH)[J]. J Clin Oncol, 2023, 41(1): 117-127.
[12] Llovet JM, Vogel A, Madoff DC, et al.Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment[J]. Cardiovasc Intervent Radiol, 2022, 45(4): 405-412.
[13] Liang L, Xu ZD, Lu WF, et al.Survival benefit from adjuvant TACE combined with Lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy[J]. Asian J Surg, 2024, 47(12): 5106-5112.
[14] Kudo M, Finn RS, Qin S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
[15] Qiao W, Wang Q, Hu C, et al.Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy[J]. Front Immunol, 2022, 13: 1019772.
[16] Li QJ, He MK, Chen HW, et al.Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial[J]. J Clin Oncol, 2022, 40(2): 150-160.
[17] Yuan Y, He W, Yang Z, et al.TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study[J]. Int J Surg, 2023, 109(5): 1222-1230.
[18] Li Y, Liu W, Chen J, et al.Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis[J]. Cancer Med, 2024, 13(1): e6836.
[19] Fu Y, Peng W, Zhang W, et al.Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis[J]. J Gastroenterol, 2023, 58(4): 413-424.
[20] Guan R, Zhang N, Deng M, et al.atients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors[J]. Int J Surg, 2024, 110(7): 4062-4073.
[21] Gatti L, Cassinelli G, Zaffaroni N, et al.New mechanisms for old drugs: insights into DNA-unrelated effects of platinum compounds and drug resistance determinants[J]. Drug Resist Updat, 2015, 20: 1-11.
[22] Bezu L, Gomes-de-Silva LC, Dewitte H, et al. Combinatorial strategies for the induction of immunogenic cell death[J]. Front Immunol, 2015, 24(6): 187.
[23] Dimeloe S, Frick C, Fischer M, et al.Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis[J]. Eur J Immunol, 2014, 44(12): 3614-3620.

编辑推荐 0

Metrics

阅读次数

全文

HTML			PDF

最新录用	在线预览	正式出版	最新录用	在线预览	正式出版
0	0	0	0	0	43

来源	本网站	其他网站

次数	24	19
比例	56%	44%

摘要

最新录用	在线预览	正式出版

0	0	50

	来源	本网站

	次数	50
	比例	100%